AVI BioPharma Announces First Quarter 2012 Financial Results and Corporate Update Conference Call
2012年5月3日 - 9:30PM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, will report first quarter 2012 financial results
after the NASDAQ Global Market closes on Thursday, May 10, 2012.
Subsequently, at 5:00 p.m., Eastern Time (2:00 p.m., Pacific time),
Chris Garabedian, AVI's president and CEO, will host a conference
call to discuss first quarter financial results and to provide a
corporate update.
The conference call may be accessed by dialing 800.659.2032 for
domestic callers and 617.614.2712 for international callers. The
passcode for the call is 33411604. Please specify to the operator
that you would like to join the "AVI BioPharma first quarter 2012
earnings call." The conference call will be webcast live under the
events section of AVI's website at www.avibio.com and will be
archived there following the call for 90 days. Please connect to
AVI's website several minutes prior to the start of the broadcast
to ensure adequate time for any software download that may be
necessary.
About AVI BioPharma AVI BioPharma is
focused on the discovery and development of novel RNA-based
therapeutics for rare and infectious diseases, as well as other
select disease targets. Applying pioneering technologies developed
and optimized by AVI, the Company is able to target a broad range
of diseases and disorders through distinct RNA-based mechanisms of
action. Unlike other RNA-based approaches, AVI's technologies can
be used to directly target both messenger RNA (mRNA) and precursor
messenger RNA (pre-mRNA) to either down-regulate (inhibit) or
up-regulate (promote) the expression of targeted genes or proteins.
By leveraging a highly differentiated RNA-based technology
platform, AVI has built a pipeline of potentially transformative
therapeutic agents, including eteplirsen, which is in clinical
development for the treatment of Duchenne muscular dystrophy, and
multiple drug candidates that are in clinical development for the
treatment of infectious diseases. For more information, visit
www.avibio.com.
AVI Investor and Media Contact: Erin Cox 425.354.5140 Email
Contact
Avi Biopharma (NASDAQ:AVII)
過去 株価チャート
から 5 2024 まで 6 2024
Avi Biopharma (NASDAQ:AVII)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Sarepta Therapeutics, Inc. (MM) (ナスダック市場): 0 recent articles
その他のAVI BioPharma, Inc.ニュース記事